A205470 Stock Overview
Humasis Co. Ltd. develops, manufactures, and markets in-vitro diagnostics for the detection of cardiac marker, fertility hormone, infectious disease, tumor marker, and cotinine for home and laboratory use in South Korea and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||₩13,500.00|
|52 Week High||₩36,450.00|
|52 Week Low||₩11,300.00|
|1 Month Change||-12.05%|
|3 Month Change||-45.34%|
|1 Year Change||-25.00%|
|3 Year Change||718.18%|
|5 Year Change||n/a|
|Change since IPO||608.66%|
Recent News & Updates
|A205470||KR Medical Equipment||KR Market|
Return vs Industry: A205470 underperformed the KR Medical Equipment industry which returned -7.5% over the past year.
Return vs Market: A205470 underperformed the KR Market which returned -14.3% over the past year.
|A205470 Average Weekly Movement||8.9%|
|Medical Equipment Industry Average Movement||5.7%|
|Market Average Movement||5.5%|
|10% most volatile stocks in KR Market||10.4%|
|10% least volatile stocks in KR Market||3.1%|
Stable Share Price: A205470 is more volatile than 75% of KR stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: A205470's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
Humasis Co. Ltd. develops, manufactures, and markets in-vitro diagnostics for the detection of cardiac marker, fertility hormone, infectious disease, tumor marker, and cotinine for home and laboratory use in South Korea and internationally. It offers pregnancy and ovulation self-test products; Hubi-Quan Pro, a self-contained and cartridge reader to provide rapid quantitative results for membrane-based lateral flow immunochromatographic assays; and various rapid test kits. The company was founded in 2000 and is based in Anyang, South Korea.
Humasis Fundamentals Summary
|A205470 fundamental statistics|
Is A205470 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|A205470 income statement (TTM)|
|Cost of Revenue||₩111.61b|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||4.42k|
|Net Profit Margin||46.98%|
How did A205470 perform over the long term?See historical performance and comparison
1.5%Current Dividend Yield
Is Humasis undervalued compared to its fair value and its price relative to the market?
Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: A205470 (₩13500) is trading below our estimate of fair value (₩1254481.07)
Significantly Below Fair Value: A205470 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: A205470 is good value based on its PE Ratio (3.1x) compared to the KR Medical Equipment industry average (12.6x).
PE vs Market: A205470 is good value based on its PE Ratio (3.1x) compared to the KR market (14x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate A205470's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: A205470 is good value based on its PB Ratio (2.3x) compared to the KR Medical Equipment industry average (2.4x).
How is Humasis forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Humasis has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Humasis performed over the past 5 years?
Past Performance Score4/6
Past Performance Score 4/6
Growing Profit Margin
Earnings vs Industry
Last years earnings growth
Earnings and Revenue History
Quality Earnings: A205470 has high quality earnings.
Growing Profit Margin: A205470's current net profit margins (47%) are higher than last year (45.8%).
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if A205470's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare A205470's past year earnings growth to its 5-year average.
Earnings vs Industry: A205470 earnings growth over the past year (622.2%) exceeded the Medical Equipment industry 30.5%.
Return on Equity
High ROE: A205470's Return on Equity (74.9%) is considered outstanding.
How is Humasis's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: A205470's short term assets (₩294.6B) exceed its short term liabilities (₩135.5B).
Long Term Liabilities: A205470's short term assets (₩294.6B) exceed its long term liabilities (₩3.2B).
Debt to Equity History and Analysis
Debt Level: A205470 is debt free.
Reducing Debt: A205470 had no debt 5 years ago.
Debt Coverage: A205470 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: A205470 has no debt, therefore coverage of interest payments is not a concern.
What is Humasis's current dividend yield, its reliability and sustainability?
Dividend Score 2/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: A205470's dividend (1.48%) is higher than the bottom 25% of dividend payers in the KR market (0.85%).
High Dividend: A205470's dividend (1.48%) is low compared to the top 25% of dividend payers in the KR market (2.72%).
Stability and Growth of Payments
Stable Dividend: Too early to tell whether A205470's dividend payments have been stable as they only just started paying a dividend.
Growing Dividend: Too early to tell if A205470's dividend payments are increasing as they only just started paying a dividend.
Earnings Payout to Shareholders
Earnings Coverage: With its low payout ratio (4.5%), A205470's dividend payments are thoroughly covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its low cash payout ratio (3.7%), A205470's dividend payments are thoroughly covered by cash flows.
How experienced are the management team and are they aligned to shareholders interests?
Jeong-Hak Cha is Chief Executive Officer of Humasis Co. Ltd.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Humasis Co. Ltd.'s employee growth, exchange listings and data sources
- Name: Humasis Co. Ltd.
- Ticker: A205470
- Exchange: KOSDAQ
- Founded: 2000
- Industry: Health Care Supplies
- Sector: Healthcare
- Implied Market Cap: ₩461.620b
- Shares outstanding: 34.19m
- Website: https://www.humasis.com
Number of Employees
- Humasis Co. Ltd.
- 37, Gunpocheomdansaneop 2-ro
- South Korea
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/12 00:00|
|End of Day Share Price||2022/05/12 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.